#USA #New York #Faruqi & Faruqi #securities litigation #ADMA Biologics

Important Legal Notice for ADMA Biologics Investors

As the deadline for a significant securities class action lawsuit approaches, ADMA Biologics, Inc. investors must be aware of their rights and potential claims. Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating allegations against the company and reminds affected investors of the critical date of August 10, 2026.

The ongoing investigation focuses on claims that ADMA Biologics engaged in questionable financial practices that misled investors. Specifically, allegations include undisclosed related-party transactions, improper revenue recognition techniques known as channel stuffing, and insufficient internal controls over financial reporting. These allegations raise significant concerns about the validity of the company's public statements regarding its financial health and future prospects.

On March 24, 2026, an investigative report from Culper Research disclosed discrepancies in ADMA Biologics' revenue reporting. The report criticized the company for inducing distributors to artificially inflate revenue figures through incentives, thereby creating a misleading portrayal of growth. This revelation resulted in a dramatic stock price decline, shedding 29% of its value in just two trading days — from $13.59 to $9.63 per share.

The class action lawsuit aims to establish accountability for investors who suffered losses during the period from August 9, 2024, to March 25, 2026. Investors who acquired securities in ADMA Biologics during this timeframe are encouraged to step forward, evaluate their eligibility, and take swift action to protect their legal interests. The court defines a lead plaintiff as the investor who demonstrates the greatest financial stake in the lawsuit and can adequately represent the interests of all affected investors. However, participation as a lead plaintiff is optional, and countless investors may still benefit from the outcome of the case without taking on that role.

Furthermore, anyone with information related to ADMA Biologics' business practices, including former employees and whistleblowers, is welcomed to contact Faruqi & Faruqi. Such insight can prove invaluable in strengthening the case against the company, ultimately assisting in the pursuit of justice for affected shareholders.

To learn more about this ongoing situation and your potential rights as an investor, please reach out to Faruqi & Faruqi directly. Their experienced attorneys offer consultations at no cost, aiming to assist investors in making informed decisions regarding their options in this lawsuits.

The strong track record of Faruqi & Faruqi in securities litigation showcases their commitment to advocate for investors’ rights, and they have recovered significant amounts for shareholders in the past. If you have been impacted by these events, do not hesitate to explore your options before the impending deadline.

Visit Faruqi & Faruqi's website or call their partner, Josh Wilson, directly at 877-247-4292 or 212-983-9330 (Ext. 1310) for further assistance. Remember, being proactive could be a critical step toward recovering your investments.